|All the writing on this page is original copy I wrote, except quotations and the definitions of pharmacology and medicinal chemistry, which are paraphrased from their respective Wikipedia articles.|
This is a Sandbox. Sure is a lot of sand in this sandbox.
My favorite subject
I took a lot of classes in pharmacy school. They ran the gamut from Biology I to Pathophysiology to Pharmacotherapy, a juggernaut 12 credit course. If I had to choose my favorite though, it would be a close race between Molecular Biology and Pharmacology/Medicinal Chemistry.
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in general biology or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.
- 1. Pharmacology is the branch of biology concerned with the study of drug action, where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.
- Medicinal chemistry
- 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties.
- 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).
I really enjoyed this course because:
- It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy
- Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called aldose reductase, which converts excess glucose into the sugar alcohol sorbitol.
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies.
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often
lazy less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A1C, or HbA1C. As the table below illustrates, incidence of complications is lower in patients with lower HbA1C levels, which correspond to stricter control over blood glucose levels (fewer spikes).
|Table 27.1 Strict vs. Loose Serum Glucose Control|
|Loss of visual acuity||14%||35%||Not measured|
Clearly, higher HbA1C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:
Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.
- Vallance, P.; Smart, T.G. (January 2006). "The future of pharmacology". British Journal of Pharmacology 147 (S1): S304–7. doi:10.1038/sj.bjp.0706454. PMC 1760753. PMID 16402118. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1760753.
- Reichard, P.; Nilsson, B.Y.; Rosenqvist, U. (1993). "The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.". New England Journal of Medicine (329): 304-309.
- Williams, D.A.; Lemke, T.L. (2002). "Chapter 27: Insulin and Oral Hypoglycemic Drugs". Foye's Principles of Medicinal Chemistry (5th ed.). Lippincott Williams & Wilkins. pp. 632. ISBN 9780683307375.